Get the Stockscreener App
0.97
2.51%
-0.025
After Hours:
1.03
0.06
+6.19%
Allarity Therapeutics Inc stock is traded at $0.97, with a volume of 66,507.
It is down -2.51% in the last 24 hours and down -19.17% over the past month.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.
See More
Previous Close:
$0.995
Open:
$1
24h Volume:
66,507
Relative Volume:
0.42
Market Cap:
$15.60M
Revenue:
-
Net Income/Loss:
$-11.90M
P/E Ratio:
-0.00471
EPS:
-206.0125
Net Cash Flow:
$-12.75M
1W Performance:
+5.21%
1M Performance:
-19.17%
6M Performance:
-38.99%
1Y Performance:
+19.46%
1-Day Range:
$0.97
$1.02
1-Week Range:
$0.90
$1.0389
52-Week Range:
$0.6138
$2.35
Allarity Therapeutics Inc Stock (ALLR) Company Profile
Name
Allarity Therapeutics Inc
Sector
Industry
Phone
401-426-4664
Address
24 SCHOOL ST., 2ND FLOOR, BOSTON
Compare ALLR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALLR
Allarity Therapeutics Inc
|
0.97 | 16.00M | 0 | -11.90M | -12.75M | -206.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.83 | 121.97B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.67 | 81.49B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
766.92 | 47.74B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.92 | 43.93B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
316.99 | 35.67B | 4.98B | 69.60M | 525.67M | 0.5198 |
Allarity Therapeutics Inc Stock (ALLR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-28-25 | Initiated | Ascendiant Capital Markets | Buy |
Allarity Therapeutics Inc Stock (ALLR) Latest News
Allarity Therapeutics doses first patients in VA-funded small cell lung cancer trial - Mugglehead Investment Magazine
Why analysts upgrade Allarity Therapeutics Inc. stockRate Hike & Real-Time Buy Zone Alerts - mfd.ru
Allarity Therapeutics doses first patients in VA-funded Phase 2 SCLC trial - TradingView
Allarity Therapeutics Doses First Patients in Phase 2 Lung Cancer Trial - marketscreener.com
Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need - The Manila Times
Allarity Therapeutics Initiates VA-Funded Phase 2 Trial of Stenoparib and Temozolomide for Relapsed Small Cell Lung Cancer - Quiver Quantitative
VA lung cancer trial tests new drug combo for patients with few options - Stock Titan
What is Allarity Therapeutics Inc. s 5 year growth outlook2025 Key Lessons & Detailed Earnings Play Strategies - mfd.ru
Why Allarity Therapeutics Inc. stock remains on buy listsWeekly Profit Report & Real-Time Volume Analysis - mfd.ru
Biotechnology company Allarity Therapeutics Inc recently filed documents with the U.S. Securities and Exchange Commission, disclosing that its selling shareholders plan to resell 255,103 shares of the company’s common stock. - Bitget
Value Recap: What is the next catalyst for Allarity Therapeutics IncTrade Risk Summary & Risk Controlled Stock Alerts - baoquankhu1.vn
What is the target price for Portman Ridge Finance Corporation stockInsider Selling & Real-Time Volume Spike Alerts - baoquankhu1.vn
Will Allarity Therapeutics Inc. stock recover after earningsJuly 2025 Snapshot & Risk Controlled Stock Alerts - mfd.ru
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Aug Setups: Will Wrap Technologies Inc face regulatory challengesJuly 2025 Weekly Recap & Entry Point Confirmation Signals - baoquankhu1.vn
Allarity Therapeutics Opens Enrollment for Phase 2 Trial in Lung Cancer - TradingView
Allarity begins phase 2 trial of stenoparib combination for lung cancer - Investing.com Nigeria
Allarity Therapeutics and US Veterans Administration open enrollment for mid-stage trial of stenoparib with temozolomide in relapsed small cell lung cancer - marketscreener.com
Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment - ChartMill
Allarity Therapeutics And US Veteran’S Administration Open Enrollment For Mid-Stage Trial Of Stenoparib With Temozolomide In Relapsed Small Cell Lung Cancer - TradingView
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Can Allarity Therapeutics Inc. keep up with sector leadersJuly 2025 Weekly Recap & Intraday High Probability Alerts - baoquankhu1.vn
Published on: 2026-02-02 00:08:12 - baoquankhu1.vn
Published on: 2026-02-09 17:34:13 - baoquankhu1.vn
Can Allarity Therapeutics Inc. disrupt its industryChart Signals & Reliable Breakout Forecasts - mfd.ru
Published on: 2026-01-29 19:48:00 - mfd.ru
Allarity Therapeutics Secures Flexible Equity Financing Facility - TipRanks
Allarity Therapeutics Signs Common Stock Purchase Agreement With Tumim Stone Capital - TradingView
Activity Recap: Will Advanced Flower Capital Inc benefit from rising consumer demand2025 Performance Recap & Growth Oriented Trade Recommendations - baoquankhu1.vn
Can Allarity Therapeutics Inc disrupt its industryMarket Activity Report & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
Short Interest in Allarity Therapeutics, Inc. (NASDAQ:ALLR) Declines By 17.1% - Defense World
Aug EndMonth: Is Allarity Therapeutics Inc backed by strong institutional buying2025 Analyst Calls & Risk Managed Investment Entry Signals - baoquankhu1.vn
Can Allarity Therapeutics Inc expand its profit margins2025 Major Catalysts & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Published on: 2026-01-16 10:01:32 - baoquankhu1.vn
Published on: 2026-01-16 08:05:07 - baoquankhu1.vn
Meme Stocks: Is Yuanbao Inc Depositary Receipt stock influenced by commodity pricesJuly 2025 Gainers & Reliable Price Action Trade Plans - baoquankhu1.vn
Market Outlook: What valuation multiples suggest for Allarity Therapeutics Inc stockJuly 2025 WrapUp & Weekly Stock Breakout Alerts - Bộ Nội Vụ
EV Market: Can Allarity Therapeutics Inc keep up with sector leadersProfit Target & Weekly Return Optimization Alerts - baoquankhu1.vn
Loss Report: Can Allarity Therapeutics Inc stock maintain growth trajectoryShare Buyback & Stepwise Trade Execution Plans - Bộ Nội Vụ
Reviewing Allarity Therapeutics (NASDAQ:ALLR) & Cardio Diagnostics (NASDAQ:CDIO) - Defense World
Market Wrap: What dividend safety score for Allarity Therapeutics Inc stockQuarterly Performance Summary & Technical Confirmation Alerts - Bộ Nội Vụ
What catalysts could drive Allarity Therapeutics Inc. stock higherJuly 2025 Weekly Recap & Weekly High Momentum Picks - Улправда
Allarity Therapeutics, Inc.Common stock (NQ: ALLR - FinancialContent
How Allarity Therapeutics Inc. stock benefits from tech adoptionMarket Risk Report & Growth Oriented Trade Recommendations - ulpravda.ru
How strong is Allarity Therapeutics Inc. stock balance sheetPrice Support Zones & Free Tap Rapid Wealth - Улправда
News | postregister.comAllarity Therapeutics, Inc.Common stock (Nasdaq:ALLR) Price Chart - FinancialContent
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on B - GuruFocus
Is Allarity Therapeutics Inc. stock a buy before product launches2026 world cup usa national team qualification young talents high defensive line winner prediction guide - ulpravda.ru
Allarity CEO says 2026 represents an ‘inflection point’ - Yahoo Finance
Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders - GlobeNewswire
Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Down 21.9% in December - Defense World
Allarity Therapeutics Inc Stock (ALLR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.18%
0.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):